These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 17321987)

  • 1. Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells.
    Yamamoto S; Yamauchi T; Kawai Y; Takemura H; Kishi S; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
    Int J Hematol; 2007 Feb; 85(2):108-15. PubMed ID: 17321987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
    Yamauchi T; Negoro E; Kishi S; Takagi K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
    Biochem Pharmacol; 2009 Jun; 77(12):1780-6. PubMed ID: 19428333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
    Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
    Seymour JF; Huang P; Plunkett W; Gandhi V
    Clin Cancer Res; 1996 Apr; 2(4):653-8. PubMed ID: 9816215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.
    Gandhi V; Estey E; Keating MJ; Plunkett W
    J Clin Oncol; 1993 Jan; 11(1):116-24. PubMed ID: 8418222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells.
    Gandhi V; Plunkett W
    Cancer Chemother Pharmacol; 1992; 31(1):11-7. PubMed ID: 1458554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of guanine arabinoside and Bcl-2 inhibitor YC137 overcomes the cytarabine resistance in HL-60 leukemia cell line.
    Nishi R; Yamauchi T; Negoro E; Takemura H; Ueda T
    Cancer Sci; 2013 Apr; 104(4):502-7. PubMed ID: 23320492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
    Danhauser L; Plunkett W; Liliemark J; Gandhi V; Iacoboni S; Keating M
    Leukemia; 1987 Sep; 1(9):638-43. PubMed ID: 3478543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology.
    Gandhi V; Robertson LE; Keating MJ; Plunkett W
    Cancer Chemother Pharmacol; 1994; 34(1):30-6. PubMed ID: 8174200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of ara-CTP levels by fludarabine and hydroxyurea in leukemic cells.
    Ahlmann M; Lanvers C; Lümkemann K; Rössig C; Freund A; Baumann M; Boos J
    Leukemia; 2001 Jan; 15(1):69-73. PubMed ID: 11243402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.
    Ramilo-Torno LV; Avramis VI
    Cancer Chemother Pharmacol; 1995; 35(3):191-9. PubMed ID: 7805176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
    Avramis VI; Wiersma S; Krailo MD; Ramilo-Torno LV; Sharpe A; Liu-Mares W; Kowck R; Reaman GH; Sato JK
    Clin Cancer Res; 1998 Jan; 4(1):45-52. PubMed ID: 9516951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
    Gandhi V; Kemena A; Keating MJ; Plunkett W
    Cancer Res; 1992 Feb; 52(4):897-903. PubMed ID: 1737352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of cytarabine-resistant leukemic cell lines established from five different blood cell lineages using gene expression and proteomic analyses.
    Negoro E; Yamauchi T; Urasaki Y; Nishi R; Hori H; Ueda T
    Int J Oncol; 2011 Apr; 38(4):911-9. PubMed ID: 21290089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML.
    Anderson E; Mehta P; Heywood J; Rees B; Bone H; Robinson G; Reynolds D; Salisbury V; Mayer L
    Leuk Res; 2018 Nov; 74():121-129. PubMed ID: 30119908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical modulation of arabinosylcytosine for therapy of leukemias.
    Gandhi V; Estey E; Keating MJ; Plunkett W
    Leuk Lymphoma; 1993; 10 Suppl():109-14. PubMed ID: 8481660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells.
    Gandhi V; Plunkett W
    Cancer Res; 1988 Jan; 48(2):329-34. PubMed ID: 3335008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High activity and incomplete cross resistance of nucleoside analogues cladribine and fludarabine versus Ara-C on leukemic cells from patients with AML.
    Löfgren C; Albertioni F; Paul C
    Ther Drug Monit; 2005 Oct; 27(5):641-6. PubMed ID: 16175139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular and clinical pharmacology of fludarabine.
    Gandhi V; Plunkett W
    Clin Pharmacokinet; 2002; 41(2):93-103. PubMed ID: 11888330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.